Sh. Mohammed, N., A. Hussain, S., Noori Ai-Karwi, I. (2014). Effects of Sub therapeutic Doses of ACE-I in Improving insulin sensitivity in Type II DM Patients. Alustath, 8(1), 14-18. doi: 10.37652/juaps.2014.121393
Nesren Sh. Mohammed; Saad A. Hussain; Isam Noori Ai-Karwi. "Effects of Sub therapeutic Doses of ACE-I in Improving insulin sensitivity in Type II DM Patients". Alustath, 8, 1, 2014, 14-18. doi: 10.37652/juaps.2014.121393
Sh. Mohammed, N., A. Hussain, S., Noori Ai-Karwi, I. (2014). 'Effects of Sub therapeutic Doses of ACE-I in Improving insulin sensitivity in Type II DM Patients', Alustath, 8(1), pp. 14-18. doi: 10.37652/juaps.2014.121393
Sh. Mohammed, N., A. Hussain, S., Noori Ai-Karwi, I. Effects of Sub therapeutic Doses of ACE-I in Improving insulin sensitivity in Type II DM Patients. Alustath, 2014; 8(1): 14-18. doi: 10.37652/juaps.2014.121393

Effects of Sub therapeutic Doses of ACE-I in Improving insulin sensitivity in Type II DM Patients

Journal of University of Anbar for Pure Science
Article 4, Volume 8, Issue 1, April 2014, Pages 14-18
Document Type: Research Paper
DOI: 10.37652/juaps.2014.121393
Authors
Nesren Sh. Mohammed1; Saad A. Hussain1; Isam Noori Ai-Karwi2
1College of Pharmacy,University of Baghdad-Iraq.
2National Center for Diabetes ,Al-Mustansriya university
Abstract
Diabetes mellitus (DM) is a complex, multifactorial and heterogeneous group of disorders characterized by endogenous insulin deficiency and/or insulin resistance. Regardless of the etiology, the disease manifests itself as a state of chronic hyperglycemia with attendant small blood vessel (microvascular) and large blood vessel (macrovascular) complications, All individuals who have DM have derangement of normal blood glucose and insulin homeostasis. Insulin receptor defects (quantitative and/or qualitative) inhibit glucose uptake by cells as in type 2 diabetes mellitus (T2DM). While Beta cell failure results in inadequate circulating insulin levels as in type 1 diabetes mellitus (T1DM).
30 patients selected with uncontrolled non insulin dependent diabetes mellitus (NIDDM) .Their average age was (44.34±7.15) years and their duration of diabetes was 8.48±8.27 years,examination and selection of patients done by the consultant physician ,assistant professor ,at the national center of treatment and research for diabetes .Essential kidney disease and hypertensive patients were excluded, we tested their blood pressure, fasting blood sugar (FBS),post postprandial glucose excursion (PPGE) and albuminuria before and after daily captopril intake for 2 months.The results showed a significant decrease (p<0.01) in PPGE (postprandial glucose excursion) , after taking angiotensin converting enzyme (ACE) inhibitor captopril mean (185 ±28.75 mg/dl) when compared before captopril intake (230±45 mg/dl) , when calculating the area under the curve. In which these results indicated a positive effect of captopril on insulin sensitivity and blood glucose level.
Keywords
ACE; Improving insulin sensitivity; Type II DM Patients
References
  1.   1.  A. Paul Chous, O.D.The New Fundamentals of Diabetes, As the public health crisis of diabetes grows, optometrists must accept their necessary role on the diabetes .health-care team, Optometric Study Center,Medical Dissertations. 2005;87(10):15-18.
  2.   2.  Stina Lindmark from the Department of Public Health and Clinical Medicine, Mechanisms in Insulin Resistance and Type 2 Diabetes Medicine,Sweden Neurohormonal .2004;67:90-94.
  3.   3.   HAROLD E. LEBOVITZ, ; Treating hyperglycemia in type 2 diabetes: New goals and strategies CLEVELAND CLINIC JOURNAL OF MEDICINE .2002;69(10):46-52.
  4.   4.  H. GIN (1), V. RIGALLEAU (1); POST-PRANDIAL HYPERGLYCEMIA. POST-PRANDIAL HYPERGLYCEMIA AND DIABETES: Diabetes & Metabolism  .2000; 26:265-272.
  5.   5.  Morris, A. D., Boyle, D. I., McMahon, A. D. et al. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Diabetes Care 1997;20, 1363–1367.
  6.   6.  Top C, Cingozbay BY, Terekeci H, Kucukardali Y, Onde ME, Danaci M: The  effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med. Res .2002;30:15-20.
  7.   7.   Gerstein HC: Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab. Res Rev. 2002;18 (3):82-85.
  8.   8.   McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003; 91:30- 37.
  9.   9.  Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension .2003;42:76-81.

10. Barham D,Trendoer P.An improved color reagent from the determination of blood glucose by the oxidative system. Analyst .1972;97:142-145.

11. Mc Elderry LA,Tarbit IF,Cassels AS.Six methods for urinary protein compared.Clin Chem.1982;28:256-260.

12. Avidnon.A,Radance.A,Monnier.L: Non fasting blood glucose is better marker of diabetic control than fasting plasma glucose in type II diabetes ; D.Care :1997;20:1822-1826.

  1. 13.  L A Velloso, F Folli, X J Sun, et al : Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A. 1996;93(22): 12490–12495.
  2. 14.  Keely S. Solomon, Ph.D. Developmentof diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens .2004 ;22(3):645-652.

15. Talma Rosenthal; Yael Erlich; Eliezer Rosenmann; et,al: Effects of Enalapril, Losartan, and Verapamil on Blood Pressure and Glucose Metabolism in the Cohen-Rosenthal Diabetic Hypertensive Rat. Hypertension. 1997;29:1260-1264.

16. Erlich Y, Rosenthal T. Contribution of bradykinin (BK) to the beneficial effects of CEI in fructose induced hyperinsulinemic rat.  International Society of Hypertension;  1996; 77;855- 857.

  1. 17.  Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005 ;46(5):821-826.

18. Shorr RI, Ray WA, , Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA.  1997 ; 278(1):40-43.

19. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf. 1996;15(2):135-157.

  1. 20.  Chelliah A, Burge MR; Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004;21(8):511-530.
  2. 21.  ZanellaMT, Kohlmann OJr, RibeiroAB. Treatment of obesity hypertension and diabetes syndrome. Hypertension. 2001 ;38(3-2):705-708.

22. Klaus Rave 1 , Sabine Flesch 1, W. Nikolaus Kühn-Velten,et,al; Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study: Profil Institute for Metabolic Research, Neuss, Germany .2005;5 :38-41.

  1. 23.  Jandeleit-Dahm, Karin AM; Tikellis, Christos,et,al;Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. Journal of Hypertension. 2005;23(3):463-473.

24. E. Torlone1, A. M.Rambotti1, G. Perriello et,al: ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with Type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension; Diabetologia , 1991; 34(2):119 – 125.

Statistics
Article View: 2,336
PDF Download: 88


Journal Management System. Powered by ejournalplus.com